728945-64-0

Usage

Uses

Used in Pharmaceutical Industry:
Anthranilic acid, 4-tert-butyl(5CI) is used as an intermediate in the synthesis of pharmaceuticals for its antimicrobial, anti-inflammatory, and antipyretic properties. Its enhanced stability and solubility due to the tert-butyl group make it a preferred compound in the development of new drugs.
Used in Dye Industry:
In the dye industry, Anthranilic acid, 4-tert-butyl(5CI) is used as a key component in the production of various dyes. Its aromatic amine nature contributes to the color and stability of the dyes, making it a valuable asset in this sector.
Used in Chemical Industry:
Anthranilic acid, 4-tert-butyl(5CI) is utilized as a versatile intermediate in the chemical industry for the production of a wide range of organic compounds. Its enhanced stability and solubility make it suitable for various chemical reactions and processes.

InChI:InChI=1/C11H15NO2/c1-11(2,3)7-4-5-8(10(13)14)9(12)6-7/h4-6H,12H2,1-3H3,(H,13,14)

Upstream product

• 103797-19-9 4-(tert-butyl)-2-nitrobenzoic acid 
• 1147530-72-0 4-tert-butyl-1-ethynyl-2-nitrobenzene 
• 1147530-71-9 (4-tert-butyl-2-nitrophenylethynyl)trimethylsilane 
• 62559-08-4 4-tert-butyl-2-nitrotoluene 
• 98-51-1 4-tert-butyltoluene 

Downstream Products

• 916168-24-6 C₁₆H₂₃NO₃ 
• 1204428-10-3 C₃₆H₄₀N₈O₂ 
• 1147530-73-1 7-tert-butyl-3-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]-3H-quinazolin-4-one 
• 1058138-97-8 C₅₈H₄₀ 

Relevant academic research and scientific papers

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: I

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.

QUINAZOLINONES

Disclosed are compounds of formula (I), wherein R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k, and Y1 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.